BRD9

Across TCGA pan-cancer cohorts, BRD9 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of BRD9’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where BRD9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BRD9 is over-expressed in tumor.

HNSC, KIRC, and STAD are the cancer types where BRD9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BRD9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	+0.946	<.001	12	view →
KIRC	Female	All	+0.605	<.001	12	view →
STAD	Female	All	+1.115	<.001	11	view →
COAD	Female	All	+0.933	<.001	10	view →
LIHC	Female	II,III,IV	+1.282	<.001	9	view →
KIRP	All	All	+0.381	<.001	9	view →
LUAD	Female	All	+0.489	<.001	8	view →
CHOL	Male	All	+2.216	<.001	5	view →
LUSC	Male	II,III,IV	+0.860	<.001	5	view →
UCEC	All	III,IV	+0.343	.028	4	view →
ESCA	All	All	+0.637	.005	2	view →
READ	All	All	+0.622	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

BRD9–HNSC

Open the HNSC breakdown →